Zheng Quan Zhi Xing·2025-08-15 16:24Summary of Key Points Core Viewpoint - The company plans to use part of the raised funds to provide interest-free loans to its wholly-owned subsidiary for the implementation of fundraising projects, which has been reviewed and approved by the sponsor institution [1][9]. Fundraising Overview - The company raised a total of RMB 1,109.25 million through its initial public offering, with a net amount of RMB 994.64 million after deducting issuance costs [1]. - The total planned investment for the fundraising projects is RMB 1,771.79 million, with the company intending to allocate RMB 994.64 million from the raised funds [2]. Use of Funds - The company previously provided an interest-free loan of RMB 50 million to its subsidiary Shenzhen Kexing Pharmaceutical for the "R&D Center Upgrade Project" [2][3]. - The current plan includes an additional interest-free loan of RMB 20 million to the same subsidiary for ongoing R&D projects, bringing the total loan amount to RMB 120 million [4][5]. Project Progress - As of June 30, 2025, the cumulative investment in the R&D Center Upgrade Project is RMB 347.46 million, with RMB 290.63 million already utilized, resulting in a shortfall of RMB 56.83 million [4]. - The remaining balance in the dedicated fundraising account for this project is RMB 73.96 million, which includes net income from financial products and bank interest [4]. Financial Data of the Subsidiary - As of December 31, 2024, the subsidiary reported total assets of RMB 535.61 million, net assets of RMB 278.31 million, operating income of RMB 316.77 million, and net profit of RMB 51.75 million [7]. Approval Process - The use of funds for the interest-free loan has been approved by the company's board and supervisory board, complying with relevant regulations [9].